According to a release issued by Glenmark Pharmaceuticals to the Bombay Stock Exchange, InvaGen filed the ANDA and obtained USFDA nod for the Fosinopril Sodium product in April 2005.
Fosinopril is an anti-hypertensive agent of the ACE Inhibitor class, with a US generic market size of $92
Glenn Saldanha, MD and CEO of Glen Pharma stated, "This agreement is in line with our strategy to partner with local US manufacturers to accelerate establishing our presence as a major player in the US market."